High prevalence of low vitamin D status in the Czech Republic: a retrospective study of 119,925 participants

Introduction

Vitamin D is essential nutrient for maintaining optimal human health throughout whole life. Its deficiency is associated with increased prevalence in osteopenia/osteoporosis, metabolic diseases (metabolic syndrome, obesity, diabetes type II), cardiovascular, neurological (neurodegenerative) and inflammatory diseases and cancer [1,2,3,4]. Vitamin D deficiency can be induced by various causes. The most common are decreased exposure to sunlight and inadequate dietary intake of vitamin D. Additionally, lower vitamin D levels can be caused by malabsorption, severe liver and kidney disease, hereditary defects in vitamin D absorption and the use of certain medications such as antiepileptic drugs or corticosteroid treatment [5,6,7].

The prevalence of vitamin D insufficiency and deficiency in population is very high. Studies have shown that a significant percentage of the global population has inadequate vitamin D levels, even in populations living in warm, sunny climates. Insufficiency and even deficiency were detected in both adults and children [8, 9].

In our study, which is the largest study of 25-hydroxyvitamin D levels in Czech population, we used multidata to determine 25-hydroxyvitamin D levels and the prevalence of low or high 25-hydroxyvitamin D levels in serum in the Czech population. Furthermore, we examined the correlations of 25-hydroxyvitamin D levels with the month of the year, that is, with the period of UV illumination, and the prevalence of influenza infection to determine whether there are fluctuations in 25-hydroxyvitamin D levels and whether these fluctuations are related to these factors.

The data obtained can be used for prevention policy, to evaluate whether 25-hydroxyvitamin D levels in the population need to be monitored, and to recommend supplementation to decision makers to reduce morbidity associated with in adequate levels of 25-hydroxyvitamin D in the population.

Methods

Study group, population

This cross-sectional retrospective study was conducted in the Czech Republic, latitude used for analyses 50° 12’ 33.93“N; longitude, 15° 49’ 57.45“E. The study included 119,925 people who visited a general practitioner’s office, medical specialists or (minority) were admitted to hospital. For the analysis, data from the period 2010 to 2020 (prior to covid pandemic) were used.

25-hydroxyvitamin D levels

Levels of 25-hydroxyvitamin D were evaluated by Architect 25-OH Vitamin D with immunoassay analyzer Architect i4000SR and by Alinity 25-OH Vitamin D Reagent Kit (new innovated version of Architect) with immunoassay analyzer ALINITY II (Abbott Laboratories, Abbott Park; USA) according to the manufacturer’s instructions. Detection range of Architect 8.5 to 389.8 nmol/L, ALINITY II 8.8 to 385.5 nmol/L.

25-hydroxyvitamin D status

25-hydroxyvitamin D status was characterized according to the Endocrine Society guidelines for clinical practice [10], which are used in the Czech Republic, including the laboratory that analyzed all blood samples used in the study as follows:

  • Normal levels, sufficiency: ≥75 nmol/L

  • Lower levels: insufficiency: 50 to <75 nmol/L

  • Deficiency <50 nmol/L

  • Higher levels: hypervitaminosis: >250 nmol/L

Homocysteine levels

Homocysteine levels were evaluated with immunoassay analyzer Architect i4000SR and ALINITY II (Abbott Laboratories, Abbott Park; USA) according to the manufacturer’s instructions (CMIA, chemiluminescent microparticle immunoassay). Detection range 1.0–500 μmol/L.

CRP levels

CRP levels were evaluated using AU5800 (Beckman Coulter, Brea; USA) and CRP latex as a reagent with detection range of 0.2–480 mg/L or ALINITY CC (Abott Laboratories, Abbott Park; USA) and CRP vario reagent with detection range of 1.0–480 mg/L according to manufacturer’s instructions (quantitative immunoturbidimetric assay).

Sunlight (hours per month)

Average value of sunshine in hours per month were recorded in 2013–2022 in Klementinum, Prague, the oldest weather station in the Czech Republic.

https://www.chmi.cz/historicka-data/pocasi/mesicni-data/mesicni-data-dle-z.-123-1998-Sb#

Sunshine hours are as follows:

January: 40.3, February: 84.4, March: 142.5, April: 184.7, May: 186.6, June: 221.3, July: 228.5, August: 213.9, September: 155.4, October: 112.8, November: 55.5, December: 47.1.

Cumulative sunlight

Modeling the Relationship Between Sunlight Exposure and 25-hydroxyvitamin D Levels

It is likely that the 25-hydroxyvitamin D levels change with a slight delay following sunlight exposure since the peak of sunlight occurs in July, while the 25-hydroxyvitamin D levels peak in August. The delayed response is evident as the rise in 25-hydroxyvitamin D after the winter period occurs in May, while the increase in sunlight starts as early as February.

The potential delay in 25-hydroxyvitamin D levels following sunlight exposure can be modeled using a weighted sum of illumination in the preceding months:

$$25-{text{hydroxyvitamin}},{text{D}},{text{level}},({text{month}}) sim mathop{sum }limits_{text{year}}left({text{Sunlight}},{text{exposure}},({text{month}})times {text{Weight}},({text{month}})right)$$
(1)

A simple weight progression is a monotonic decrease in the contribution of sunlight exposure to 25-hydroxyvitamin D levels over time. In this model, the weight of sunlight has the maximum impact in the sample month, and its value decreases towards the preceding months. The dependency is modeled using an exponential curve given by:

$${rm{Weight}},({rm{month}})=exp left(frac{{rm{month}}}{{rm{decrease}}}right),{rm{for}}; {rm{month}}=1..12$$
(2)

This function is subsequently normalized so that the sum of weights equals one. The steepness of the decrease was optimized to achieve maximum correlation between the measured and modeled 25-hydroxyvitamin D data. Optimization was performed using the ‘optimize‘ function in R version 4.3.2 (2023-10-31) (R Core Team (2023). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. <https://www.R-project.org/>.).

Flu prevalence

The percentage of flu positive samples in January: 22.1, February: 32.2, March: 23.6, April: 15.5, May: 5.1, June: 0.1, July: 0.0, August: 0.0, September: 0.0, October 1.0, November: 3.5, December: 9.9.

http://atlas.ecdc.europa.eu/public/index.aspx

Statistics

Statistical analysis was conducted in R version 4.3.2 (2023-10-31) (R Core Team (2023). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. <https://www.R-project.org/>.).

For the assessment of the normal distribution of data, we used the Anderson-Darling test. Since the normality of 25-hydroxyvitamin D was rejected, we reported median, lower and upper quartiles, and minimal and maximal values. For correlation analysis, we used the Spearman test. The level of statistical significance, alpha, was set to 0.05.

Results

Demographic data

Data from 119,925 individuals were analyzed in this study. Among participants 75,273 were females and 44,652 were males aged between 0 and 100 years (median 51 and 46 years). Participants were further divided into groups according to age (Table 1).

Table 1 Participants according to age (age groups).
Full size table

25-hydroxyvitamin D levels

The levels of 25-hydroxyvitamin D differs according to age. The highest were in children aged 0–1 years (86.60 nmol/L). The lowest in the oldest participants (48.75 nmol/L) (Table 2). There was significant difference between the males and females. Males had lower levels when compared to females (p < 0.001) (Table 3).

Table 2 Vitamin D levels in each age group.
Full size table
Table 3 Vitamin D levels sex differences.
Full size table

Prevalence of 25-hydroxyvitamin D status; deficiency, insufficiency, sufficiency, hypervitaminosis

The 25-hydroxyvitamin D status was determined in selected age groups. The lowest 25-hydroxyvitamin deficiency and insufficiency was in the infants. 65.6% of infants had sufficient 25-hydroxyvitamin D levels, higher levels were in females (65.8%). The highest prevalence of deficiency was in the 91–100 (51.8%; female 57.9%) but lowest prevalence of sufficiency was in the 6–15 group (19.2%; females 17%). Hypervitaminosis was very rare and occurred more often in females (Table 4).

Table 4 The prevalence of vitamin D deficiency, insufficiency and sufficiency in children and adults.
Full size table

Levels of homocysteine

Levels of homocysteine (µmol/L) were higher in males compared to females (Table 5).

Table 5 Homocysteine levels in males and females.
Full size table

Levels of CRP

Levels of CRP (mg/L) were higher in females compared to males (Table 6).

Table 6 CRP levels in males and females.
Full size table

Correlations

We found a strong correlation between 25-hydroxyvitamin D and age, month of the year, sunlight (hours per months in the sampling months), cumulative sunlight (sunlight hour per year) and flu positivity in all participants, females and males.

During the optimization of weighting coefficients, we found the maximum Spearman correlation (rho = 0.3177699) for the decrease (Eq. (2)) of 6.56234. Our optimized model indicates that the contribution of sunlight exposure to 25-hydroxyvitamin D levels decreases with the time elapsed since the sample collection. Assuming that the contribution of sunlight exposure would be greatest at the time of collection, corresponding to 100%, the contributions in the previous eleven months were 85.9%, 73.7%, 63.3%, 54.4%, 46.7%, 40.1%, 34.4%, 29.6%, 25.4%, 21.8%, and 18.7% respectively.

Correlation analysis revealed that 25-hydroxyvitamin D levels are strongly affected by age, sunlight, homocysteine levels and by sex; males are more susceptible to lower levels of 25-hydroxyvitamin D (Table 7, Fig. 1).

Table 7 Correlations between vitamin D levels (nmol/L) and selected parameters: age, month of the year, sunlight (hours per months), cumulative sunlight (sunlight hour per year), flu positivity and homocysteine and CRP levels.
Full size table
Fig. 1: Distribution of vitamin D for male and female subjects stratified by explanatory solid parameters.
figure 1

Data are displayed using box plots (red for female and green for male) delineating the lower quartile, median, and upper quartile, with whiskers indicating the minimum and maximum but no longer than 1.5 interquartile range. Vitamin D levels by age group (years) – A; by calendar month – B; by cumulative sunlight in one month (hours) – C; by influenza prevalence (% positivity) – D.

Full size image

The top left graph (A) shows the dependence of 25-hydroxyvitamin D on age. The age ranges for the baskets of this graph are not uniform; their choice was based on the expected dynamics of 25-hydroxyvitamin D change and is described in detail with the numbers of subjects observed in Table 4. The order of the baskets corresponds to the increasing age of the subjects. The top right graph (B) shows the distribution of 25-hydroxyvitamin D levels when the population is divided into baskets according to the month of testing. In this case, each box plot includes persons of various ages. The highest levels were reached in September and August. The bottom left plot (C) represents the same baskets as the top right, but this time, they are ordered by cumulative sunshine duration as calculated by the model for each month – see results for more. The cumulative sunshine data in hours are given in the x-axis description, and the baskets are sorted in ascending order. The plot demonstrates a positive linear dependence on solar cumulative shining, which the correlation analysis (Table 7) confirms. The lower right graph (D) shows the distribution of 25-hydroxyvitamin D levels when the cohort is divided into baskets according to the percentage of influenza detected in independent samples. In this graph, each box plot includes individuals of various ages tested in different months. The percentages of infected samples are given in the x-axis description, and the bins are sorted in ascending order. The plot demonstrates a negative linear relationship confirmed by correlation analysis (Table 7).

Correlation between 25-hydroxyvitamin D levels and CRP was also found (Table 7, Figs. 2, 3; correlation in females and males are in supplementary data).

Fig. 2: Correlation between vitamin D levels and homocysteine levels in all participants.
figure 2

Each point represents an individual study subject, trendline is the linear black line; r2 coefficient of determination.

Full size image
Fig. 3: Correlation between vitamin D levels and CRP levels in all participants.
figure 3

Each point represents an individual study subject, trendline is the linear black line; r2 coefficient of determination.

Full size image

Discussion

Adequate amounts of vitamin D are essential for maintaining our health. In our study, we found different 25-hydroxyvitamin D levels in age groups with a high prevalence of insufficiency and deficiency and confirmed the correlation between selected parameters (age, sex, sunlight, flu, and homocysteine).

Currently, there is an ongoing discussion regarding the optimal vitamin D levels necessary for human health. Emerging evidence suggests that a serum 25-hydroxyvitamin D concentration of 50 nmol/L may be fully sufficient, as opposed to the previously recommended level of 75 nmol/L. However, in our study, we adhered to the reference values provided by the laboratory that processed our samples, which are based on the Endocrine Society guidelines used in the Czech Republic. These guidelines define 25-hydroxyvitamin D sufficiency as levels ≥75 nmol/L, insufficiency as 50–75 nmol/L, and deficiency as <50 nmol/L.

To maintain consistency and comparability, our discussion references studies that utilize the same classification ranges. Despite the evolving perspectives on 25-hydroxyvitamin D sufficiency, our findings indicate a high prevalence of 25-hydroxyvitamin D insufficiency and deficiency (levels below 75 nmol/L) across all age groups in the Czech population, while the occurrence of hypervitaminosis was very rare.

Worldwide prevalence of vitamin D deficiency in the total population is high, similar to what we see in our study. Deficiency is present in the population regardless of the location of the country in which the study was conducted. Cui et al. processed data from 308 studies from 2000 to 2022 involving 7.9 million people from 81 countries. 202 studies (7,634,261 participants) showed that the prevalence of 30 nmol/L was 15.7%, 50 nmol/L 47.9% and 75 nmol/L 76.6%. Previous study of Cui et al. focused on the prevalence of vitamin D deficiency in US population (71,685 participants) and described the trends in vitamin D levels from 2001 to 2018. Moderate and severe deficiency was detected in 22.0% and 2.6% (levels 25–50 nmol/L and <25 nmol/L subjects. The prevalence of insufficiency was 40.9% (levels 50–75 nmol/L) while the prevalence of sufficiency was 34.5% [9, 11]. The studies also show that even populations living in sunny areas have problems with inadequate vitamin D levels. Meta-analysis of 96 studies (a total of 227,758 individuals) by Mendes et al. showed that the prevalence of vitamin D deficiency in population of South America is 34.76% [12]. Lebanon study by Harkous et al. evaluated vitamin D deficiency in 66,127 people. The situation in Europe is even worse. Even in just one of the sunniest countries, the prevalence of vitamin D deficits is quite high. Xyda et al. evaluated levels of vitamin D in Greek and Cypriot population. They found that 72.7% (mean level 53.75 nmol/L) of Greek and 69.3% of Cypriot (mean level 64.5 nmol/L) population had inadequate levels of vitamin D [13]. Manios et al. focused on vitamin D status in Southern European and Eastern Mediterranean countries and conducted a systematic review using data from 103 studies with 630,039 subjects. They found that the vitamin D deficiency is, surprisingly, high and suggested that there is the pandemic of vitamin D hypovitaminosis in Europe [14]. The Central Europe and Western Europe has similar problem. Dutch study by Brouwer-Brolsma et al. showed that in 2857 participants aged ≥65 years, the prevalence of vitamin D deficiency (<50 nmol/L) is 45% [15]. In the German study by Rabenberg et al., the prevalence of vitamin D levels <30 nmol/L was 30.2% and the levels >50 nmol/L had 61.6% [16]. The data from Ukraine from 2021 showed that the prevalence of vitamin D deficiency (levels >50 nmol/L) is 26% and insufficiency (50–<75 nmol/L) was 37% [17].

Levels of vitamin D and prevalence in newborns, infants, and children to 15 years

The youngest participants in our study had the highest levels of vitamin D and the lowest prevalence of vitamin D deficiency (8%). Sufficient vitamin D levels were found in 66% of children aged 0–1 years. We assumed that this result mirrors general acceptance of guidelines of the Czech Pediatric Society (2019) on vitamin D supplementation as a prevention of disorders of bone metabolism, growth, and rickets [18]. Vitamin D supplementation in infants, regardless of the method of nutrition (breastfeeding, formula feeding is recommended in most European countries, including the UK. The study by Uday et al. showed high adherence to recommended vitamin D supplementation across countries [19]. The prevalence of vitamin D deficiency in infants has been documented in countries where there are no guidelines for vitamin D supplementation in children 0–12 months [20, 21].

This positive effect of supplementation continues for the following year of the children’s age. Vitamin D levels, in our study, gradually decreased to the age of 10 years. In children aged 2–5 years the prevalence of sufficiency was 32.2%. The prevalence of deficiency was 25%. In children aged 6–15, the prevalence of sufficiency was only 19.2% and the prevalence of vitamin D deficiency 38.3%.

Similar results were found various studies analyzing the levels of vitamin D in children, e.g. Zhang et al. They evaluated vitamin D status in children (n = 6953) aged 0–6 years. In children 0–1 year of age, toddlers and preschool children the median values of vitamin D were 69.4, 62.3, and 50.85 nmol/L, respectively. The levels of vitamin D were seasonally dependent, higher in summer and lower in winter [22]. Vitamin D deficiency and its dependence of season in toddlers confirmed Chaoimh et al. and Stoungjerg et al. The prevalence of deficiency was 26.7% and 38% [23, 24].

As in our study, high vitamin D deficiencies in school children and adolescents have also been reported in many other studies regardless of their origin, including studies from very sunny locations such as Costa Rica, Indonesia and Australia [8, 25,26,27]. In Chinese study by Hu et al., the prevalence of vitamin D deficiency (lower 50 nmol/L) was 65.98% [28]. On the European continent, studies have been carried out in the Mediterranean area, for example in Italy. Galeazzi et al. measured vitamin D levels in 1706 Italian school-age children. The prevalence of sufficiency (>75 ng/mL) was in 36% while deficiency (25–50 ng/mL) was in 21% and lower levels was in spring and winter [29]. In the Czech Republic, Sochorova et al. showed that in the children aged 5 and 9 (419 subjects) sufficient levels (>75 nmol/L) had only 34% of children. Most children had insufficiency (40%; 50–75 nmol/L). They also found that levels of vitamin D varied according to season. The highest levels were detected in autumn and lowest in spring [30].

Vitamin D levels in adults and elderly

Our study showed that the levels of 25-hydroxyvitamin D in adults were stable from 15 to 50 years (the prevalence of 25-hydroxyvitamin D deficiency was 16–30 and 31–50 groups (43.5% and 40.7%), then, in older people (51–70 and 71–90 group), we detected the increase in the levels of 25-hydroxyvitamin D and decrease in the prevalence of 25-hydroxyvitamin D deficiency (33.2% and 34.2%) until the age of 90 (51.8%). While the prevalence of 25-hydroxyvitamin D deficiency was higher in younger men compared to women, the opposite was observed in the oldest group. This increase in population aged 50–90 may be due to more frequent preventive examinations in GPs and an increase in morbidity which requires visits to a specialist who can prescribed 25-hydroxyvitamin D supplementation [31,32,33]. The subsequent decline could be attributed to the fact that such elderly people are often already polymorbid, bedridden and have limited exposure to sunlight. Diet, its composition, quality and ability to absorb nutrients are also problematic. A number of studies evaluated 25-hydroxyvitamin D levels in very old people and centenarians. Kupisz-Urbańska et al. compared the levels of 25-hydroxyvitamin D in adults 65-years old and centenarians. They found that the levels of 25-hydroxyvitamin D in older people were lower, like in our study [34]. Foroni et al. enrolled in their Brazilian study people aged ≥80 years. Severe deficiency (<25 nmol/L) and deficiency (<50 nmol/L) were observed in 13% and 56% subjects [35]. In German study, Rabenberg et al. evaluated levels of 25-hydroxyvitamin D in population 65 to 79 years. The prevalence of deficiency (<30 nmol/L) was 32.9% in females and 26.6% in males. Only 5.7% females and 8.2% males had sufficient (>75 nmol/L) levels of 25-hydroxyvitamin D [36]. Other German study by Conzade et al. confirmed that the prevalence of deficiency is positively associated with age. The prevalence of deficiency (<50 nmol/L) was 44% in the 65–74 age group and increased to 74% in the 85–93 age group [37].

Correlations

We confirmed that the levels of 25-hydroxyvitamin D depend on the season (months, sunlight, cumulative sunlight), sex, age, incidence of flu, homocysteine, and CRP.

Regarding the seasonal dependence of 25-hydroxyvitamin D levels, our study is consistent with the results of numerous other studies. Some of them were mentioned above. Levels of 25-hydroxyvitamin D decreased during winter and early spring. This effect depends mainly on exposure to sunlight. Australian study by Elliott et al. described that in summer, in all locations, 5–10 min outdoors between 8 am and 4 pm most days of the week, when 35% of the body surface is exposed, is sufficient to maintain current 25(OH)D concentrations. In winter, at mid and higher latitudes, to maintain 25-hydroxyvitamin D concentration, it is necessary to be outdoors in the middle of the day and 10% of the body surface must be exposed for more than 45 min [38].

Study by Fayet-Moore who determined 25-hydroxyvitamin D status in healthy Australian office workers during summer and during winter. 25-hydroxyvitamin D levels were higher in late summer compared to late winter. 25-hydroxyvitamin D deficiency (<50 nmol/L) was detected in 29 (summer) and 42% (winter) subjects [39].

In Slovenian study, by Osredkar et al. found that summer levels of 25-hydroxyvitamin D are significantly higher compared to winter levels, but the levels of 25-hydroxyvitamin D binding protein did not differ [40].

In our study, we also found an interesting association between cumulative annual sunlight and 25-hydroxyvitamin D levels. We found no other study that reports on this. 25-hydroxyvitamin D levels negatively correlated with age which is in accordance with other studies, and male gender, although various studies showed opposite trends [41].

Our results further revealed a correlation between 25-hydroxyvitamin D and the incidence of influenza evidenced by detection of specific antibodies in blood. We have not found a study that confirms a correlation between 25-hydroxyvitamin D levels and influenza, but there are many studies that show that supplementation, i.e., increasing 25-hydroxyvitamin D levels, can reduce the risk of influenza infection. Meta-analysis by Zhu et al. used data from 10 studies with total 4859 participants and showed that supplementation with 25-hydroxyvitamin D can reduce the risk of influenza infections (relative risk 0.78) [42]. A meta-analysis by Martineau et al. confirmed the positive role of 25-hydroxyvitamin D in the prevention of respiratory infectious diseases. They analyzed data from 25 studies with total 11,321 participants aged 0–95 years. In all participants, 25-hydroxyvitamin D supplementation reduced risk of acute respiratory tract infections [43].

We also revealed a negative association between 25-hydroxyvitamin D levels and CRP and homocysteine. Nowadays, the levels of both parameters are frequently assessed, and it has been shown that their increasing values are related to an unhealthy lifestyle and the presence of a number of chronic diseases in which inflammation plays an important role. CRP and homocysteine serve as risk and prognostic factors for cardiovascular, metabolic and neurodegenerative diseases, among others. Similarly, low 25-hydroxyvitamin D levels are associated with the development of these diseases [44, 45].

Zhou et al. conducted the study with data from 294,970 unrelated participants. They confirmed the inverse association between 25-hydroxyvitamin D and CRP in participants with inadequate levels of 25-hydroxyvitamin D and suggested that this association may be caused by 25-hydroxyvitamin D deficiency because 25-hydroxyvitamin D has anti-inflammatory properties [46]. Laird et al. focused on 25-hydroxyvitamin D status and inflammation in the elderly. They measured 25-hydroxyvitamin D and CRP levels in 5381 participants over the age of 50 years. The results showed that participants with sufficient 25-hydroxyvitamin D levels had lower CRP levels. Participants with 25-hydroxyvitamin D deficiency were more likely to have higher levels of CRP [47]. The association between 25-hydroxyvitamin D and homocysteine levels in studies has been investigated among patients suffering from a selected disease, not in the whole population. Verdoia et al. described that patients with cardiovascular disease had lower levels of 25-hydroxyvitamin D, which was also associated with an increase in homocysteine levels [48]. Amer et al. evaluated 25-hydroxyvitamin D and homocysteine levels in 14,630 asymptomatic participants and found an inverse relationship between 25-hydroxyvitamin D and homocysteine in participants with 25-hydroxyvitamin D levels of 21 ng/ml or less [49].

The results of our study suggest that for the Czech population, it would be advisable to set rules for regular 25-hydroxyvitamin D supplementation, especially during late autumn, winter, and early spring.

Conclusion

This is the largest study of 25-hydroxyvitamin D levels in Czech population. Only limited and earlier studies are available, which do not provide such a comprehensive view of the prevalence of 25-hydroxyvitamin D deficiency in the Czech population. In our study, we confirmed a high prevalence of low 25-hydroxyvitamin D status, which depended on age, sex, sun exposure, prevalence of influenza, CRP and homocysteine levels. The results suggest that a program should be developed to educate the population about the positive impact of 25-hydroxyvitamin D on human health and recommend regular supplementation in doses that ensure adequate 25-hydroxyvitamin D levels.

Limitations

Although we found correlations between 25-hydroxyvitamin D levels and sunshine hours, we acknowledge that sunshine duration is an imperfect proxy for 25-hydroxyvitamin D synthesis. Factors such as the solar zenith angle—which affects UVB radiation intensity—and individual behaviors like skin exposure, sunscreen use, and lifestyle significantly influence 25-hydroxyvitamin D production. Our reliance on aggregate sunshine hours does not capture these nuances. Future studies should incorporate more precise measures of UVB exposure and consider individual factors. Nevertheless, our findings highlight seasonal variations in 25-hydroxyvitamin D levels and the importance of supplementation during months with minimal endogenous synthesis.

First, as a retrospective study utilizing data over a ten-year period, we were unable to control for potential confounding variables. We lacked detailed individual data on factors influencing 25-hydroxyvitamin D status, such as dietary intake, 25-hydroxyvitamin D supplementation, skin pigmentation, body mass index (BMI), physical activity, clothing habits, time spent outdoors, and sunscreen use, which could substantially impact serum 25-hydroxyvitamin D levels.

Second, despite our large sample size, the study population may not fully represent the entire Czech population. Participants were individuals seeking medical care, potentially introducing selection bias, as they may differ in health status or behaviors from the general population. We also lacked data on socioeconomic status, education level, or other demographic factors that might influence 25-hydroxyvitamin D status.

Third, although we used standardized assays, assay variability exists between laboratories and methods. We did not provide specific data on assay precision and accuracy, nor confirm participation in international standardization programs like DEQAS or VDSP, which may affect comparability with other studies.

Finally, we did not assess the impact of chronic diseases, medications, or genetic factors affecting 25-hydroxyvitamin D metabolism. Conditions such as malabsorption syndromes, liver or kidney disease, and the use of certain medications (e.g., anticonvulsants, corticosteroids) can significantly influence 25-hydroxyvitamin D levels. Not accounting for these factors limits our ability to attribute findings solely to external factors like sunlight exposure.

Despite these limitations, our study offers valuable insights into the prevalence of 25-hydroxyvitamin D deficiency in the Czech Republic, highlighting the need for public health interventions to address this widespread issue.

Related Articles

Role of pancreatic lipase inhibition in obesity treatment: mechanisms and challenges towards current insights and future directions

The worldwide health emergency of obesity is closely connected to how dietary fats are metabolized, whereas the process is significantly influenced by pancreatic lipase (PL), an enzyme critical for lipid hydrolysis into fatty acids. This narrative review employs a methodological approach utilizing literature searches of PubMed data up to March 2024. The search term criteria encompasses keywords related to the role, mechanism, challenges, and current and future treatments of pancreatic lipase in obesity with an overall references is 106. This paper offers a comprehensive explanation of the role of PL, underlining its significance in the digestive process and lipid imbalances that contribute to obesity and by extension, its impact on obesity development and progression. Additionally, it delves into the dual functionality of the pancreas, emphasizing its impact on metabolism and energy utilization which, when dysregulated, promotes obesity. A focal point of this review is the investigation into the efficacy, challenges, and adverse effects of current pancreatic lipase inhibitors, with orlistat being highlighted as a primary current drug delivery. By discussing advanced obesity treatments, including the exploration of novel anti-obesity medications that target specific biological pathways, this review underscores the complexity of obesity treatment and the necessity for a multifaceted approach. In conclusion, this paper emphasizing the importance of understanding the role of enzymes like pancreatic lipase mechanistic and adopting a multidisciplinary approach to treatment and side effects of current obesity drugs and explore new emerging therapeutic strategies for more effective obesity management.

Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects

The muscular system plays a critical role in the human body by governing skeletal movement, cardiovascular function, and the activities of digestive organs. Additionally, muscle tissues serve an endocrine function by secreting myogenic cytokines, thereby regulating metabolism throughout the entire body. Maintaining muscle function requires iron homeostasis. Recent studies suggest that disruptions in iron metabolism and ferroptosis, a form of iron-dependent cell death, are essential contributors to the progression of a wide range of muscle diseases and disorders, including sarcopenia, cardiomyopathy, and amyotrophic lateral sclerosis. Thus, a comprehensive overview of the mechanisms regulating iron metabolism and ferroptosis in these conditions is crucial for identifying potential therapeutic targets and developing new strategies for disease treatment and/or prevention. This review aims to summarize recent advances in understanding the molecular mechanisms underlying ferroptosis in the context of muscle injury, as well as associated muscle diseases and disorders. Moreover, we discuss potential targets within the ferroptosis pathway and possible strategies for managing muscle disorders. Finally, we shed new light on current limitations and future prospects for therapeutic interventions targeting ferroptosis.

Type 2 immunity in allergic diseases

Significant advancements have been made in understanding the cellular and molecular mechanisms of type 2 immunity in allergic diseases such as asthma, allergic rhinitis, chronic rhinosinusitis, eosinophilic esophagitis (EoE), food and drug allergies, and atopic dermatitis (AD). Type 2 immunity has evolved to protect against parasitic diseases and toxins, plays a role in the expulsion of parasites and larvae from inner tissues to the lumen and outside the body, maintains microbe-rich skin and mucosal epithelial barriers and counterbalances the type 1 immune response and its destructive effects. During the development of a type 2 immune response, an innate immune response initiates starting from epithelial cells and innate lymphoid cells (ILCs), including dendritic cells and macrophages, and translates to adaptive T and B-cell immunity, particularly IgE antibody production. Eosinophils, mast cells and basophils have effects on effector functions. Cytokines from ILC2s and CD4+ helper type 2 (Th2) cells, CD8 + T cells, and NK-T cells, along with myeloid cells, including IL-4, IL-5, IL-9, and IL-13, initiate and sustain allergic inflammation via T cell cells, eosinophils, and ILC2s; promote IgE class switching; and open the epithelial barrier. Epithelial cell activation, alarmin release and barrier dysfunction are key in the development of not only allergic diseases but also many other systemic diseases. Recent biologics targeting the pathways and effector functions of IL4/IL13, IL-5, and IgE have shown promising results for almost all ages, although some patients with severe allergic diseases do not respond to these therapies, highlighting the unmet need for a more detailed and personalized approach.

Targeting of TAMs: can we be more clever than cancer cells?

With increasing incidence and geography, cancer is one of the leading causes of death, reduced quality of life and disability worldwide. Principal progress in the development of new anticancer therapies, in improving the efficiency of immunotherapeutic tools, and in the personification of conventional therapies needs to consider cancer-specific and patient-specific programming of innate immunity. Intratumoral TAMs and their precursors, resident macrophages and monocytes, are principal regulators of tumor progression and therapy resistance. Our review summarizes the accumulated evidence for the subpopulations of TAMs and their increasing number of biomarkers, indicating their predictive value for the clinical parameters of carcinogenesis and therapy resistance, with a focus on solid cancers of non-infectious etiology. We present the state-of-the-art knowledge about the tumor-supporting functions of TAMs at all stages of tumor progression and highlight biomarkers, recently identified by single-cell and spatial analytical methods, that discriminate between tumor-promoting and tumor-inhibiting TAMs, where both subtypes express a combination of prototype M1 and M2 genes. Our review focuses on novel mechanisms involved in the crosstalk among epigenetic, signaling, transcriptional and metabolic pathways in TAMs. Particular attention has been given to the recently identified link between cancer cell metabolism and the epigenetic programming of TAMs by histone lactylation, which can be responsible for the unlimited protumoral programming of TAMs. Finally, we explain how TAMs interfere with currently used anticancer therapeutics and summarize the most advanced data from clinical trials, which we divide into four categories: inhibition of TAM survival and differentiation, inhibition of monocyte/TAM recruitment into tumors, functional reprogramming of TAMs, and genetic enhancement of macrophages.

Responses

Your email address will not be published. Required fields are marked *